- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.01. | GENFLEET-B (02595): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, FEBRUARY 9, 2026 | 4 | HKEx | ||
| 23.01. | GENFLEET-B (02595): NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 23.01. | GENFLEET-B (02595): (1) PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME (2) PROPOSED ADOPTION OF THE H SHARE INCENTIVE SCHEME (3) PROPOSED AUTHORISATION ... | 2 | HKEx | ||
| 20.01. | GENFLEET-B (02595): PROPOSED ABOLISHMENT OF THE SUPERVISORY COMMITTEE AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 05.12.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST SITE INITIATED IN A REGISTRATIONAL STUDY OF GFH375 FOR METASTATIC PANCREATIC CANCER, AS FIRST-IN-WORLD ... | 1 | HKEx | ||
| 24.11.25 | GENFLEET-B (02595): PROPOSED ADOPTION OF THE H SHARE OPTION SCHEME AND THE H SHARE INCENTIVE SCHEME | 1 | HKEx | ||
| GENFLEET THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.10.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN A PHASE IB/II STUDY OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, COMBINED WITH CETUXIMAB ... | 2 | HKEx | ||
| 21.10.25 | Verastem stock falls after GenFleet's PDAC study shows lower efficacy data | 1 | Investing.com | ||
| 21.10.25 | GENFLEET-B (02595): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 21.10.25 | GENFLEET-B (02595): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 21.10.25 | GENFLEET-B (02595): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 20.10.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT EFFICACY DATA OF GFH375, AN ORAL KRAS G12D (ON/OFF) INHIBITOR, FOR PANCREATIC DUCTAL ADENOCARCINOMA PATIENTS ... | 1 | HKEx | ||
| 19.10.25 | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | 605 | Business Wire | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| 16.10.25 | GENFLEET-B (02595): FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD | - | HKEx | ||
| 15.10.25 | GENFLEET-B (02595): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | - | HKEx | ||
| 15.10.25 | GENFLEET-B (02595): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS | 1 | HKEx | ||
| 30.09.25 | GENFLEET-B (02595): 2025 INTERIM REPORT | 1 | HKEx | ||
| 29.09.25 | GENFLEET-B (02595): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED WITH GFH276, A MOLECULAR GLUE PAN RAS (ON) INHIBITOR, IN A PHASE I/II STUDY TREATING RAS-MUTANT ... | - | HKEx | ||
| 19.09.25 | GENFLEET-B (02595): DATE OF BOARD RESOLUTIONS AND DATE OF PUBLICATION OF INTERIM REPORT | 1 | HKEx | ||
| 19.09.25 | BRIEF: GenFleet shares double in heavily oversubscribed IPO | 1 | Bamboo Works |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| SPYGLASS PHARMA | 26,400 | 0,00 % | SpyGlass Pharma Prices IPO At $16 Per Share | WASHINGTON (dpa-AFX) - SpyGlass Pharma, Inc. (SGP), a late-stage biopharmaceutical company, announced the pricing of its initial public offering of 9.38 million shares at $16 per share.The company... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen |
Das Unternehmen GENFLEET THERAPEUTICS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENFLEET THERAPEUTICS SHANGHAI INC finden Sie auf Wallstreet Online.